GDF-15 drugs for Non-Small Cell Lung Cancer
2 tracked GDF-15 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the GDF-15 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 Phase 2
Head-to-head evidence: Ponsegromab vs Visugromab